Charles River, Pfizer ink marketing, distribution pact

As per the agreement, Charles River is expected to take up the responsibility for supplying the research models throughout a range of therapeutic areas like neuroscience, diabetes and cardiovascular disease.

Charles River Global Research Model Services corporate vice president Iva Morse said the use of genetically modified research models continues to emerge as an important tool to allow scientists in their research to target specific disease states and genetic markers.

"We appreciate that Pfizer has selected Charles River to bring their models to market, and the biomedical research community will undoubtedly benefit from access to Pfizer’s world-class transgenic model portfolio," Morse said.